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Pulse Pressure is a Stronger Predictor Than Systolic Blood Pressure
for Severe Eye Diseases in Diabetes Mellitus
Masahiko Yamamoto, MD; Kazuya Fujihara, MD, PhD; Masahiro Ishizawa, MD; Taeko Osawa, MD; Masanori Kaneko, MD;
Hajime Ishiguro, MD, PhD; Yasuhiro Matsubayashi, MD; Hiroyasu Seida; Nauta Yamanaka; Shiro Tanaka, PhD; Satoru Kodama, MD, PhD;
Hiruma Hasebe, MD, PhD; Hirohito Sone, MD, PhD, FACP
Background-—Evidence of the role of systolic blood pressure (SBP) in development of severe diabetic retinopathy is not strong,
although the adverse effect of low diastolic blood pressure has been a partial explanation. We assessed the predictive ability of
incident severe diabetic retinopathy between pulse pressure (PP) which considers both SBP and diastolic blood pressure,
compared with SBP.
Methods and Results-—Eligible patients (12 242, 83% men) aged 19 to 72 years from a nationwide claims database were analyzed
for a median observational 4.8-year period. Severe diabetic retinopathy was defined as vision-threatening treatment-required
diabetic eye diseases. Multivariate Cox regression analysis revealed that hazard ratios (95% CI) of treatment-required diabetic eye
diseases for 1 increment of standard deviation and the top tertile compared with the bottom tertile were 1.39 (1.21–1.60) and
1.72 (1.17–2.51), respectively, for PP and 1.22 (1.05–1.41) and 1.43 (0.97–2.11), respectively, for SBP adjusted for age, sex, body
mass index, hemoglobin A1c, fasting plasma glucose, lipids, and smoking status. In a model with SBP and PP simultaneously as
covariates, the hazard ratios of only PP (hazard ratios [95% CI], 1.57 [1.26–1.96]) but not SBP (0.85 [0.68–1.07]) were statistically
significant. Delong test revealed a significant difference in the area under the receiver operating characteristic curve between PP
and SBP (area under the receiver operating characteristic curve [95% CI], 0.58 [0.54–0.63] versus 0.54 [0.50–0.59]; P=0.03). The
strongest predictor remained as hemoglobin A1c (area under the receiver operating characteristic curve [95% CI], 0.80 [0.77–
0.84]).
Conclusions-—After excluding the significant impact of glycemic control, PP in comparison with SBP is a better predictor of severe
diabetic retinopathy, suggesting a role of diastolic blood pressure and arterial stiffness in pathology. ( J Am Heart Assoc. 2019;8:
e010627. DOI: 10.1161/JAHA.118.010627.)
Key Words: blood pressure • diabetic mellitus • hemoglobin A1c • pulse pressure • pulse pressure • systolic blood
pressure • vision-threatening treatment-required diabetic eye diseases
S evere diabetic retinopathy (DR) has been a major causeof vision loss and an impaired quality of life in patients
with diabetes mellitus. Generally, hypertension mainly
focused on high systolic blood pressure (SBP) values is
believed to be an excellent predictor of incident DR
regardless of its severity. However, with regard to incident
progressive DR, it has been reported that SBP is not
necessarily associated with this outcome.1 Moreover, a
recent meta-analysis showed2 that strict blood pressure
control is not significantly effective in preventing progressive
DR, which has been partially explained by the adverse effect
of low diastolic blood pressure (DBP). These results imply
that evidence for a role of SBP in developing severe DR is not
strong.
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It is hypothesized that high pulse pressure (PP), which
considers low DBP in addition to high SBP, is a better
indicator of future development of severe DR compared
with high SBP only. To test this hypothesis, we investigated
the risk factors for severe retinopathy using our large




In our analysis we used data from a national health
insurance claim-based database3 in Japan consisting of
3 000 000 people who are insured by a health insurance
provider for company employees. Details of the claims data
were described previously.3,4 The data, analytical methods,
and study materials will not be made available to other
researchers for purposes of reproducing the results or
replicating the procedure. Although patients aged 19 to
72 years who had been followed for at least 3 years
between April 1, 2008 and March 31, 2012 were initially
included and followed up until August 31, 2015, patients for
whom we did not have sufficient information initially for
analysis, such as follow-up periods, were subsequently
excluded. Among 280 329 individuals who met these
criteria, we included data on 17 158 individuals with
diabetes mellitus in the present study. Of these, 4916
individuals who did not have full health examination data
were further excluded. Finally, this study included 12 242
individuals (Figure S1).
Clinical and Laboratory Measurements
The participating patients were classified as having diabetes
mellitus based on their fasting plasma glucose (FPG), hemoglobin
A1c (HbA1c) and claims database data. Criteria for diabetes
mellitus were FPG≥7.0 mmol/L orHbA1c ≥6.5% or bothwithout
antidiabetic drug prescription or the use of an antidiabetic drug
prescription regardless of FPG or HbA1c.4 All facilities measured
blood pressure (BP) in accordance with the guidelines of the
Japanese Society of Hypertension.5 These guidelines recom-
mended that BP is measured twice by the oscillometric method
and the results averaged in medical checkups in Japan.5
Outcome Measures
Criteria for vision-threatening treatment-required diabetic eye
diseases (TRDED) were a composite of: (1) the diagnosis of
DR and/or diabetic maculopathy and/or diabetic macular
edema (DME); and (2) the administration of medical proce-
dures such as retinal photocoagulation treatment and/or pars
plana vitrectomy and/or intraocular injection treatment with
steroids and anti-vascular endothelial growth factor agents.
The incidence of these was determined according to claims
using International Classification of Diseases, Tenth Revision
(ICD-10) codes for DR, diabetic maculopathy, or DME in E
103, 113, or 143, and medical procedures. The examination
of the claims data enabled us to confirm that all participants
had no past history of a previous TRDED before baseline.
Statistical Analysis
Categorical variables were expressed as numerals and per-
centages. Continuous variables were expressed as the
meanSD or median and interquartile range. For comparison
between the cases and non-cases groups, Chi squared tests
were used for the categorical variables. For the continuous
variables, either the unpaired Student t test or Mann-Whitney U
test was used, depending on the distribution of the 2 groups.
Several Cox proportional-hazards regression models identified
variables related to the incidence of TRDED. Covariates
included age, sex, body mass index, HbA1c, fasting plasma
glucose, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglycerides, and smoking status.
To explore potential non-linear relationships, we used
multivariate-adjusted generalized additive models with a
spline function of 4 degrees of freedom. Unadjusted overall
time to the incidence of TRDED was indicated by Kaplan–
Meier analysis with log-rank tests.
To compare the predictive ability between 2 variables, we
assessed discriminative ability by calculating the area under
the receiver operating characteristic curve (AUCROC) and
compared the 2 AUCROCs using the DeLong method.6
Clinical Perspective
What Is New?
• To our knowledge, this is the first longitudinal, historical
cohort study to report that pulse pressure had a stronger
predictive effect on the incidence of severe diabetic
retinopathy than systolic blood pressure using a large
number of nationwide participants over a long observational
period.
What Are the Clinical Implications?
• This study implies the importance of diastolic blood
pressure in addition to systolic blood pressure and the
difficulty of administering antihypertensive treatments for
prevention of severe diabetic retinopathy leading to vision
loss given the current lack of any therapy that exclusively
targets pulse pressure.
• These findings suggest the necessity of considering pulse
pressure in addition to systolic blood pressure.
DOI: 10.1161/JAHA.118.010627 Journal of the American Heart Association 2
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Analyses were performed using SPSS (version 19.0,
Chicago, IL) and SAS packages version 9.4 (SAS Institute
Inc, Cary, NC). Statistical significance was considered for
P<0.05. The study design was consistent with the tenets of
the Declaration of Helsinki. This study was approved by the
Ethics Committee of Niigata University and the requirement
for informed consent was waived.
Results
Baseline Characteristics and Incidence of TRDED
During Follow-Up
Among 12 242 patients, a total of 165 TRDED occurred
during the observational period of a median of 4.8 years.
Cumulative incidence rate of TRDED was 2.83 per 1000
person-years. Baseline characteristics of all patients as well
as those who had or had not experienced TRDED during
the observational period are summarized in Table 1.
Individuals with TRDED were significantly older and had
higher levels of SBP, PP, and HbA1c compared with those
without.
Hazard Ratios of BP Components for TRDED
Risk factors for incident TRDED investigated by the multivari-
ate Cox model are shown in Table 2. HbA1c was the most
strongly associated with the incidence of TRDED with an HR
(95% CI) per 1-SD for elevations of  2.2 (1.9–2.5) in any
model. The hazard ratio (HR) (95% CI) of TRDED for an
increment of 1-SD was larger for PP (1.39 [1.21–1.60]) than
for SBP (1.22 [1.05–1.41]) after adjusting for covariates
(Table 2). In a model involving both SBP and PP simultane-
ously as covariates, the HR of only PP but not SBP was
statistically significant (Table 2, model 3). When we reana-
lyzed our database adding a past history of cardiovascular
diseases and the use of medications for dyslipidemia,
hypertension, and diabetes mellitus at baseline as covariates,
these relationships were unchanged (Table S1). In models
involving either DBP or mean BP as the only covariate for BP,
the HRs for TRDED for each 1-SD for elevations were not
significant; 0.93 (0.79–1.10) for DBP and 1.06 (0.91–1.24) for
mean BP (Table S2).
Spline Curves for the Risk of TRDED With Regard
to PP, SBP, and HbA1c
Figure 1 shows spline curves for the log risk of TRDED with
regard to PP, SBP, and HbA1c. Compared with the linear
model, the spline model improved the goodness of fit for
HbA1c (P<0.01) but not for PP (P=0.48) and SBP (P=0.16).
There was no clear threshold above which the risk of TRDED
was greatly elevated in any of the 3 variables.




P Value(n=12 242) (n=12 077) (n=165)
Sex (male, %) 10 158 (83) 10 024 (83) 134 (81) 0.544
Age (y), mean (SD) 489 489 508 0.001
Body mass index (kg/m2), mean (SD) 25.84.6 25.84.6 26.14.5 0.386
Systolic blood pressure (mm Hg), mean (SD) 13116 13116 13421 0.033
Diastolic blood pressure (mm Hg), mean (SD) 8011 8011 8013 0.728
Pulse pressure (mm Hg), mean (SD) 5011 5011 5414 <0.001
HbA1c (%), mean (SD) 6.91.4 6.91.4 9.02.3 <0.001
HbA1c (mmol/mol), mean (SD) 5216 5115 7525 <0.001
Fasting plasma glucose (mmol/L), mean (SD) 7.82.3 7.72.2 10.34.2 <0.001
LDL cholesterol (mmol/L), mean (SD) 3.40.9 3.40.9 3.30.9 0.644
HDL cholesterol (mmol/L), mean (SD) 1.50.4 1.50.4 1.50.4 0.288
Triglycerides (mmol/L), median (IQR) 1.4 (1.0–2.2) 1.4 (1.0–2.2) 1.4 (1.0–2.2) 0.511
Current smoking (%) 5009 (41) 4949 (41) 60 (36) 0.231
Data are presented as numbers, meansSDs, median (IQR), or percentages. HbA1c indicates hemoglobin A1c; HDL, high-density lipoprotein; IQR, interquartile; LDL, low-density
lipoprotein; TRDED, treatment-required diabetic eye diseases.
DOI: 10.1161/JAHA.118.010627 Journal of the American Heart Association 3
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HRs and Cumulative Incidence of TRDED for the
Stratified Tertiles of PP, SBP, and HbA1c
We categorized the patients into tertiles according to HbA1c
(≤6.4, 6.5–6.9, ≥7.0%), SBP (≤124, 125–136, ≥137 mm Hg),
DBP (≤76, 77–84, ≥85 mm Hg), and PP (≤45, 46–54,
≥55 mm Hg). Multivariate Cox analysis shows the HRs for the
stratified tertiles of PP, SBP, and HbA1c (Table 3). Figure 2
shows the corresponding cumulative incidences of TRDED for
the stratified tertiles of these variables. Among the 3 variables,
the HR for the top tertile compared with the bottom tertile was
the largest for HbA1c (HR [95% CI], 5.04 [3.36–7.58]). In
particular, when the HbA1c values were stratified into 6
categories with increments of 0.5% (Table S3, Figure S2), the
HRs for TRDED among patients with HbA1c of 8.1% to 8.5% and
≥8.6% were 5.91 (2.87–12.17) and 14.10 (8.07–24.60),
respectively, compared with those whose HbA1c was ≤6.5%.
The HR of TRDED for the top tertile compared with the bottom
tertile was larger for PP (HR [95% CI], 1.72 [1.17–2.51] than for
SBP (HR [95% CI], 1.43 [0.97–2.11]).
Table 2. HR With 95% CI of Baseline Values for Each Variable for TRDED Risk Analyzed by Cox Models
Characteristic
Model 1 Model 2 Model 3
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age, y 1.04 (1.02–1.06) <0.001 1.03 (1.01–1.05) 0.002 1.03 (1.01–1.05) 0.001
Sex, male 1.22 (0.81–1.86) 0.346 1.38 (0.90–2.11) 0.140 1.41 (0.92–2.16) 0.113
Body mass index
Per 5 kg/m2 1.09 (0.91–1.31) 0.368 1.10 (0.92–1.31) 0.317 1.13 (0.94–1.36) 0.190
Per 1-SD 1.08 (0.91–1.28) 1.09 (0.92–1.28) 1.12 (0.95–1.33)
Systolic blood pressure
Per 10 mm Hg 1.13 (1.03–1.23) 0.008 NA 0.91 (0.79–1.04) 0.175
Per 1-SD 1.22 (1.05–1.41) NA 0.85 (0.68–1.07)
Pulse pressure
Per 10 mm Hg NA 1.35 (1.19–1.53) <0.001 1.50 (1.23–1.84) <0.001




1.70 (1.56–1.86) <0.001 1.73 (1.59–1.89) <0.001 1.73 (1.59–1.89) <0.001
Per 1 mmol/mol 1.05 (1.04–1.06) 1.05 (1.04–1.06) 1.05 (1.04–1.06)
Per 1-SD 2.14 (1.89–2.41) 2.19 (1.94–2.47) 2.19 (1.94–2.47)
Fasting plasma glucose
Per 1 mmol/L 1.02 (0.97–1.08) 0.506 1.01 (0.96–1.07) 0.714 1.01 (0.96–1.07) 0.706
Per 1-SD 1.04 (0.92–1.18) 1.02 (0.91–1.16) 1.02 (0.91–1.16)
HDL cholesterol
Per 1 mmol/L 1.36 (0.88–2.11) 0.171 1.35 (0.87–2.10) 0.176 1.39 (0.90–2.17) 0.141
Per 1-SD 1.13 (0.95–1.34) 1.13 (0.95–1.34) 1.14 (0.96–1.36)
LDL cholesterol
Per 1 mmol/L 0.77 (0.64–0.92) 0.003 0.77 (0.64–0.92) 0.004 0.77 (0.64–0.92) 0.004
Per 1 SD 0.79 (0.67–0.92) 0.79 (0.67–0.93) 0.79 (0.67–0.93)
Log-triglycerides
Per 1 0.84 (0.63–1.13) 0.247 0.86 (0.65–1.14) 0.299 0.88 (0.66–1.18) 0.402
Per 1-SD 0.90 (0.76–1.07) 0.91 (0.77–1.09) 0.93 (0.78–1.11)
Current smoker 0.88 (0.63–1.23) 0.450 0.84 (0.60–1.18) 0.311 0.83 (0.59–1.16) 0.265
A total of 165 patients developed TRDED. Model 1=adjusted for age, sex, body mass index, SBP, HbA1c, fasting plasma glucose, LDL cholesterol, HDL cholesterol, triglycerides,
smoking status. Model 2=model 1 plus additional adjustment for pulse pressure and minus adjustment for SBP. Model 3=model 1 plus additional adjustment for pulse pressure. HbA1c
indicates hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not applicable; SBP, systolic blood pressure; TRDED, treatment-required diabetic eye
diseases.
DOI: 10.1161/JAHA.118.010627 Journal of the American Heart Association 4


















 http://ahajournals.org by on August 24, 2020
HR for the Top Tertile Compared With the
Combination of the Lower and Middle Tertiles
With Regard to PP, SBP, and HbA1c
Similar to the above results, the HR for the top tertile versus
middle+bottom tertiles was larger for PP (HR [95% CI], 1.66
[1.20–2.29] than for SBP (HR [95% CI], 1.33 [0.96–1.85])
(Table S4). This result was in line with the visual inspection of
the Kaplan–Meyer analysis (Figure 2) indicating that gaps
between curves for the top tertile and the middle+bottom
tertiles were larger for PP than for SBP.
Combined Roles of SBP With DBP for TRDED
We additionally stratified the patients into tertiles according
to DBP (≤76, 77–84, ≥85 mm Hg). Table S5 shows the result
of Cox regression analysis using the stratified tertiles of DBP
in addition to SBP, instead of PP. When the combination of the
bottom tertile of SBP and the bottom tertile of DBP was the
reference group, the HR of TRDED was larger for the bottom
tertile of DBP than for the middle tertile of DBP in any SBP
group. In particular, the HR was smaller in the low SBP and
the middle DBP tertiles than in the reference group (HR [95%
CI], 0.53 [0.25–1.14]).
Risk of TRDED in Each of the PP and SBP Tertiles
Combined With HbA1c Tertiles
Figure S3 shows the risk of TRDED in each of the PP and SBP
tertiles combined with the HbA1c tertiles. Compared with the
referent (ie, combination of the bottom HbA1c tertile and
bottom PP/SBP tertile), the HR (95% CI) for the extreme
tertiles (ie, top HbA1c tertile and top PP/SBP tertile) was
12.51 (3.83–40.91) for PP and 5.68 (2.45–13.17) for SBP.
The association between the PP tertiles and the risk of TRDED
was not significant among individuals in the middle and
bottom HbA1c tertiles. Among those in the top HbA1c tertile,
a significantly positive association between tertiles and risk of
TRDED was observed for PP (P trend=0.027) unlike that for
SBP (P trend=0.517). However, interactions between HbA1c
and PP were not statistically significant (P=0.298).
AUCROC for the Incidence of TRDED
Table 4 shows discriminative ability as indicated by the
AUCROCs for HbA1c, PP, and SBP. The AUCROC (95% CI) was
0.80 (0.77–0.84) for HbA1c, 0.58 (0.54–0.63) for PP and 0.54
(0.50–0.59) for SBP. The Delong test indicated that the
AUCROC for HbA1c was significantly larger than that for PP
(P<0.001) and SBP (P<0.001); the AUCROC for PP was larger
than that for SBP (P=0.03).
Discussion
This is the first large-scale, long-term longitudinal study to
compare PP and SBP in terms of their association with
incident severe DR. All previous studies7–12 except for 1
study13 that examined the associations between PP and DR
used cross-sectional research, which would fail to prove
whether high PP preceded the incidence of DR. The only
longitudinal study included only 86 patients and did not
compare SBP with PP.13
We specified only cases with vision impairment requiring
an ophthalmological intervention, which is of great signif-
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Figure 1. Spline curves of log risk of TRDED (solid line) with 95% CIs (broken line) in relationship to PP (A), SBP (B), and HbA1c (C),
with rug plots describing distributions of PP, SBP, or HbA1c. (A and B) are adjusted for age, sex, bone mass index, HbA1c, fasting plasma
glucose, LDL cholesterol, HDL cholesterol, triglycerides, and smoking status. Adjustment for (C) is (A) plus additional adjustment for SBP
and minus adjustment for HbA1c. HbA1c indicated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PP,
pulse pressure; SBP, systolic blood pressure; TRDED, treatment-required diabetic eye diseases.
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an ophthalmological intervention makes an enormous differ-
ence in urgency, the impact on quality of life and the medical
cost between severity stages of DR indicating the need for an
ophthalmological intervention. This still holds true even
though there has been remarkable progress in the manage-
ment of DR in the past few decades, including the use of anti-
vascular endothelial growth factor agents.14,15
We indicated that compared with SBP, PP was not only more
strongly associated with but also a stronger predictor of severe
DR. Moreover, relevant to the stronger association of PP with
TRDED than SBP,we confirmed adverse prognostic outcomes in
patients with low DBP (≤76 mm Hg, in this study).
Although determining the underlying mechanisms for the
enhancement of the progression of DR or DME through the
superiority of elevated PP to that of elevated SBP is beyond an
epidemiological study, there may be a plausible explanation
for the current finding. For example, although only cross-
sectionally, arterial stiffness has been associated with DR in
type 2 diabetes mellitus.16 It is possible that the arterial
stiffness plays an important role in deteriorating DR given that
an elevated PP, which is a surrogate marker of the arterial
stiffness, is attributed to a decrease in DBP in addition to an
increase in SBP.17 Possible contributors to progression of DR
with which PP rather than SBP is predominantly associated
are needed to be identified in future studies.
Of note, several analyses that we conducted indicated that
it is most important to monitor HbA1c among possible
traditional risk factors in predicting severe DR. At each level
of HbA1c, PP is a much better predictor than SBP. In
particular, the significant association between PP and the
incidence of TRDED was observed in the top tertile of HbA1c
(≥7.0%). This finding suggested that priority should be given to
monitoring HbA1c to detect those at high risk for severe DR
and that determining PP should be secondary to identifying
patients with poor glycemic control.
In our study, serum low-density lipoprotein levels were
found to be lower in patients with TRDED and HRs for TRDED
were significantly decreased in accordance with increases in
low-density lipoprotein cholesterol. Only the Tromsø Eye
Study18 showed results similar to ours. When we reanalyzed
our database adding the past history of cardiovascular
disease and use of medications for dyslipidemia, hyperten-
sion, and diabetes mellitus at baseline as covariates
(Table S1), the statistical significance of the negative
relationship between low-density lipoprotein cholesterol and
incident TRDED disappeared. These factors might have
affected and changed this negative relationship.
The strengths of this study are its large number of
nationwide participants over a long observational period, an
extremely low rate of lost-to-follow-up participants, and
accurate identification of TRDED based on actual medical
practice. These strengths reflect the advantages of a claim-
based database. Moreover, thanks to the well-organized
public health insurance system that equally covers all citizens
in Japan, ophthalmologists can choose treatment according to
what is best for each patient’s situation without considering
economic status. This is another large advantage of the use of
the claim-based database or management-based outcomes in
this country.
Several limitations of the current study should be
addressed. First, we had no information on types and duration
of diabetes mellitus and fundus examinations. However, since
Table 3. HR With 95% CI for Baseline Values of PP, SBP, and HbA1c Tertiles for TRDED Risk Analyzed by Cox Models
Variables Cases/Total n HR (95% CI) P Value P Trend
A. PP (mm Hg)
Bottom tertile (≤45) 48/4109 1.00 (reference) 0.008
Middle tertile (46–54) 48/4239 1.07 (0.71–1.60) 0.754
Top tertile (≥55) 69/3894 1.72 (1.17–2.51) 0.006
B. SBP (mm Hg)
Bottom tertile (≤124) 53/4389 1.00 (reference) 0.186
Middle tertile (125–136) 48/3934 1.16 (0.77–1.72) 0.481
Top tertile (≥137) 64/3919 1.43 (0.97–2.11) 0.071
C. HbA1c (% in National Glycohemoglobin Standardization Program)
Bottom tertile (≤6.4) 13/4389 1.00 (reference) <0.001
Middle tertile (6.5–6.9) 23/3876 2.29 (1.15–4.58) 0.019
Top tertile (≥7.0) 129/3977 7.97 (4.36–14.57) <0.001
B, C=adjusted for age, sex, body mass index, SBP, HbA1c, FPG, LDL cholesterol, HDL cholesterol, triglycerides, and smoking status. A=B plus additional adjustment for PP and minus
adjustment for SBP. FPG indicates fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; PP, pulse pressure; SBP,
systolic blood pressure; TRDED, treatment-required diabetic eye diseases.
DOI: 10.1161/JAHA.118.010627 Journal of the American Heart Association 6
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it is well known that the prevalence of type 1 diabetes
mellitus is extremely low in East Asia, most patients in our
analysis were considered to have type 2 diabetes mellitus.
Second, only baseline data were used for this analysis;
therefore, therapeutic management during the observational
period could have influenced the results.
Third, possible BP measurement errors could bias the
results. Errors can be particularly large for PP rather than for
SBP given that the difference between the 2 measurements
(ie, SBP and DBP) enlarge the measurement error. However,
since the strength of association tends to be weaker with the
measurement error, the expected difference in the strength of
association between PP and SBP would be rather enlarged
compared with the observed difference. Therefore, we should
not have to change the conclusion. Nevertheless, the
possibility of measurement errors should always be consid-
ered when interpreting the results.
Fourth, instead of using outcomes predominantly based on
criteria for results of fundus examinations (i.e, which would be
more important and superior to definitions based on claims
data), we identified TRDED based on comprehensive judgment
of ophthalmologists in terms of the necessity for treatment in
real-world clinical settings, which might be vulnerable to
observer bias. However, recent progress in examination and
treatment technologies minimize this bias. Moreover, although
fluorescein angiography has been widely used and remains a
fundamental and useful diagnostic modality for classification of
DR, severe adverse effects, including anaphylaxis, are of
concern.
Lastly, among TRDED patients in general, there is large
heterogeneity in severe eye diseases that are comprehen-
sively designated as TRDED. However, unfortunately, we could
not perform sensitivity analysis based on the underlying eye
diseases. One reason is that some ophthalmological treat-
ments (such as vitrectomy or retinal photocoagulation) are
adapted not for a single treatment-specific eye disease but for
several severe eye diseases. Another reason is that some
TRDED patients may not only have a single eye disease but ≥2
eye diseases (eg, proliferative DR and DME) simultaneously. It
would therefore become complicated and difficult to clearly
distinguish one from the other using information in the
database.
We could not detect the thresholds of PP, SBP, and HbA1c
above which the risk of TRDED was steeply elevated. For
example, Hammes and colleagues showed that BP ≥150/
90 mm Hg could impact on the development of advanced
retinopathy by logistic regression analysis in patients with
type 1 diabetes mellitus.20 However, few studies have
investigated BP cut-off values for DR risk. Further research
is needed to determine the cut-off value of PP for detection or
early treatment of patients at high risk of sight-threatening DR
in terms of maintaining quality of life or controlling medical
expenditures for ophthalmological interventions.
Figure 2. Cumulative incidence of TRDED according to tertiles of PP, systolic blood pressure, and glycated hemoglobin determined by the
Kaplan–Meier method. (A) Pulse pressure (dotted line, pulse pressure ≥55 mm Hg; black line, pulse pressure 46–54 mm Hg; dashed line, pulse
pressure ≤45 mm Hg); (B) SBP (dotted line, systolic blood pressure ≥137 mm Hg; black line, systolic blood pressure 125–136 mm Hg; dashed
line, systolic blood pressure ≤124 mm Hg) and (C) hemoglobin A1c (dotted line, HbA1c ≥7.0%; black line, hemoglobin A1c 6.5–6.9%; dashed
line, hemoglobin A1c ≤6.4%) levels at baseline. TRDED indicates treatment-required diabetic eye diseases.
Table 4. AUCROC for the Incidence of Treatment-Required
Diabetic Eye Diseases Using Conventional Risk Factors and
Blood Pressure Values







PP vs SBP PP vs HbA1c HbA1c vs SBP
P value 0.027 <0.001 <0.001
Data are AUCROC and 95% CI. Results from AUCROC analysis with the DeLong test of area
under the curvedifference.AUCROC indicatesareaunder the receiveroperatingcharacteristic
curve; HbA1c, hemoglobin A1c; PP, pulse pressure; SBP, systolic blood pressure.
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Conclusion
PP is not only more strongly associated with incident DR but
is a stronger predictor of severe DR than SBP, suggesting the
importance of DBP in addition to SBP and the difficulty of
administering antihypertensive treatments for prevention of
severe DR leading to vision loss given the current lack of any
therapy that exclusively targets PP. However, priority should
be given to monitoring HbA1c for identifying patients at high
risk of severe DR.
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Table S1. HR with 95% CI of baseline values for each variable for TRDED risk analyzed by Cox models. 








Characteristic HR (95% CI) P value   HR (95% CI) P value   HR (95% CI) P value 
Age (years) 1.03 (1.01-1.06) 0.008  1.03 (1.00-1.05) 0.026  1.03 (1.00-1.05) 0.027 
Sex (male) 1.03 (0.66-1.60) 0.914  1.15 (0.73-1.81) 0.551  1.17 (0.74-1.85) 0.499 
 
Body mass index          
   Per 5 kg/m2 0.98 (0.79-1.21) 0.830  0.99 (0.80-1.22) 0.917  1.00 (0.81-1.25) 0.974 
   Per 1-SD 0.98 (0.80-1.19)   0.99 (0.81-1.20)   1.00 (0.82-1.22)  
Systolic blood pressure         
   Per 10 mmHg 1.13 (1.02-1.25) 0.020  NA   0.95 (0.81-1.11) 0.504 
   Per 1-SD 1.22 (1.03-1.44)   NA   0.92 (0.71-1.19)  
Pulse pressure          
   Per 10 mmHg NA   1.30 (1.13-1.50) <0.001  1.38 (1.11-1.73) 0.005 
   Per 1-SD NA   1.34 (1.15-1.57)   1.43 (1.12-1.83)  
HbA1c         
   Per 1% (11mmol/mol) 1.64 (1.47-1.83) <0.001  1.66 (1.49-1.85) <0.001  1.66 (1.49-1.84) <0.001 
   Per 1 mmol/mol  1.05 (1.04-1.06)   1.05 (1.04-1.06)   1.05 (1.04-1.06)  
   Per 1-SD 2.02 (1.73-2.37)   2.06 (1.76-2.40)   2.05 (1.76-2.39)  
Fasting plasma glucose (mmol/L) 
 
 
        
   Per 1 mmol/L 1.03 (0.97-1.10) 0.352  1.03 (0.96-1.10) 0.416  1.03 (0.96-1.10) 0.396 
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HDL cholesterol         
   Per 1 mmol/L 1.35 (0.85-2.14) 0.210  1.37 (0.86-2.18) 0.188  1.39 (0.87-2.23) 0.169 
   Per 1-SD 1.12 (0.94-1.35)   1.13 (0.94-1.36)   1.14 (0.95-1.37)  
LDL cholesterol         
   Per 1 mmol/L 0.86 (0.70-1.05) 0.139  0.86 (0.70-1.05) 0.146  0.86 (0.70-1.06) 0.152 
   Per 1-SD 0.87 (0.72-1.05)   0.87 (0.73-1.05)   0.87 (0.73-1.05)  
Log-Triglycerides          
   Per 1 0.93 (0.68-1.29) 0.666  0.95 (0.69-1.31) 0.741  0.96 (0.69-1.32) 0.798 
   Per 1-SD 0.96 (0.79-1.17)   0.97 (0.80-1.18)    0.98 (0.80-1.19)  
 
Current smoker 0.90 (0.62-1.32) 0.600  0.87 (0.60-1.28) 0.484  0.87 (0.59-1.27) 0.454 
Antihypertensive medication use 
 
0.96 (0.63-1.49) 0.870  0.97 (0.63-1.48) 0.870  0.99 (0.64-1.53) 0.965 
Antidiabetic medication use 3.14 (2.14-4.61) <0.001  3.09 (2.11-4.54) <0.001  3.06 (2.09-4.50) <0.001 
Antidyslipidemic medication use 1.08 (0.69-1.68) 0.751  1.08 (0.69-1.68) 0.744  1.07 (0.68-1.67) 0.774 
Past history of cardiovascular diseases 0.55 (0.17-1.75) 0.308  0.54 (0.17-1.71) 0.293  0.53 (0.17-1.70) 0.285 
Table S1: Table 2, additionally adjusted for antihypertensive medication use, antidiabetic medication use, antidyslipidemic medication use and past history of cardiovascular diseases. 
This limits the sample size to 10,751. 132 patients developed TRDED. Model 1=adjusted for age, sex, BMI, SBP, HbA1c, FPG, LDL cholesterol, HDL cholesterol, TG, smoking 
status, medication use for hypertension, dyslipidemia, and diabetes mellitus, past history of cardiovascular diseases. Model 2=model 1 plus additional adjustment for PP and minus 
adjustment for SBP. Model 3=model 1 plus additional adjustment for PP. Abbreviations: BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; HbA1c, 
hemoglobin A1c; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; NA, not applicable; PP, pulse pressure; SBP, systolic blood pressure; SD, standard 
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Table S2. HR with 95% CI of baseline values of each variable for TRDED risk analyzed 
by Cox models. 
 
 Model 1    Model 2  
Variables HR (95% CI) P value   HR (95% CI) P value 
Age (years) 1.04 (1.02-1.07) <0.001  1.04 (1.02-1.06) <0.001 
Sex (male) 1.22 (0.80-1.86) 0.353  1.19 (0.78-1.81) 0.415 
Body mass index       
   Per 5 kg/m2 1.19 (0.99-1.43) 0.064  1.14 (0.95-1.37) 0.164 
   Per 1 SD 1.17 (0.99-1.39)   1.13 (0.95-1.34)  
Diastolic blood pressure      
   Per 10 mmHg 0.94 (0.81-1.09) 0.409  NA  
   Per 1 SD 0.93 (0.79-1.10)   NA  
Mean blood pressure       
   Per 10 mmHg NA   1.05 (0.92-1.19) 0.470 
   Per 1 SD NA   1.06 (0.91-1.24)  
HbA1c      
   Per 1% (11 mmol/mol) 1.68 (1.54-1.83) <0.001  1.68 (1.54-1.83) <0.001 
   Per 1 mmol/mol 1.05 (1.04-1.06)   1.05 (1.05-1.06)  
   Per 1 SD 2.09 (1.85-2.36)   2.10 (1.86-2.37)  
Fasting plasma glucose 
 
 
     
   Per 1 mmol/L 1.03 (0.97-1.09) 0.359  1.03 (0.97-1.08) 0.386 
   Per 1 SD 1.06 (0.94-1.20)   1.06 (0.93-1.20)  
HDL cholesterol      
   Per 1 mmol/L 1.49 (0.96-2.32) 0.076  1.43 (0.92-2.22) 0.111 
   Per 1 SD 1.17 (0.98-1.39)   1.15 (0.97-1.37)  
LDL cholesterol      
   Per 1 mmol/L 0.77 (0.64-0.92) 0.003  0.77 (0.64-0.91) 0.003 
   Per 1 SD 0.79 (0.67-0.92)   0.79 (0.67-0.92)  
Log-Triglycerides       
   Per 1 0.90 (0.67-1.21) 0.481  0.87 (0.65-1.16) 0.348 
   Per 1 SD 0.94 (0.79-1.12)    0.92 (0.77-1.10)  
Current smoker 0.86 (0.62-1.21) 0.383  0.88 (0.63-1.23) 0.450 
 
Model 1=adjusted for age, sex, body mass index, DBP, HbA1c, FPG, LDL cholesterol, HDL 
cholesterol, TG, smoking status. Model 2=model 1 plus additional adjustment for MBP and minus 
adjustment for DBP. Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose; 
HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-
density lipoprotein; MBP, mean blood pressure; NA, not applicable; TG, triglycerides; TRDED, 
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Table S3. HR with 95% CI for baseline values of six categories of HbA1c for TRDED risk analyzed by Cox models.  
 
Variables Cases/Total n HR (95% CI) P value P trend 
HbA1c (% in NGSP)     
   ≤ 6.5 22/5733 1.00 (reference)  <0.001 
   6.6 - 7.0 20/2876 1.90 (1.03-3.51) 0.040  
   7.1 - 7.5 17/1191 3.60 (1.89-6.85) <0.001  
   7.6 - 8.0 10/702 3.50 (1.64-7.47) 0.001  
   8.1 - 8.5 12/452 5.91 (2.87-12.17) <0.001  
   ≥ 8.6 84/1288 14.10 (8.07-24.60) <0.001  
 
Adjusted for age, sex, body mass index, SBP, HbA1c, FPG, LDL cholesterol, HDL cholesterol, TG, and smoking status. Abbreviations: CI, confidence 
interval; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density 
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Table S4. HR with 95% CI of TRDED for the top tertile compared with the combination of the lower and middle tertiles with regard to PP, 
SBP, and HbA1c. 
 
Variables Cases/Total n HR (95% CI) P value 
A. PP (mmHg)    
middle + bottom tertile (≤ 54) 96/8348 1.00 (reference)  
top tertile (≥ 55) 69/3894 1.66 (1.20-2.29) 0.002 
B. SBP (mmHg)    
   middle + bottom tertile (≤ 136) 101/8323 1.00 (reference)  
top tertile (≥ 137) 64/3919 1.33 (0.96-1.85) 0.089 
C. HbA1c (% in NGSP)    
   middle + bottom tertile (≤ 6.9) 36/8265 1.00 (reference)  
   top tertile (≥ 7.0) 129/3977 5.04 (3.36-7.58) <0.001 
 
A, C = adjusted for age, sex, body mass index, PP, HbA1c, FPG, LDL cholesterol, HDL cholesterol, TG, and smoking status. B = A plus additional 
adjustment for SBP and minus adjustment for PP. Abbreviations: CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin 
A1c; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; PP, pulse pressure; SBP, systolic blood pressure; TG, 
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Table S5. Combined roles of SBP with DBP for TRDED.  
 
SBP (mmHg) DBP (mmHg) HR (95% CI) P value 
  bottom tertile (≤ 124) bottom tertile (≤ 76) 1.00 (reference)  
  middle tertile (125-136) bottom tertile (≤ 76) 1.29 (0.72-2.30) 0.390 
  top tertile (≥ 137) bottom tertile (≤ 76) 3.03 (1.52-6.05) 0.002 
bottom tertile (≤ 124)  middle tertile (77-84) 0.53 (0.25-1.14) 0.105 
middle tertile (125-136) middle tertile (77-84) 1.09 (0.63-1.87) 0.757 
  top tertile (≥ 137) middle tertile (77-84) 1.46 (0.79-2.69) 0.231 
  bottom tertile (≤ 124) top tertile (≥ 85) 1.55 (0.65-3.68) 0.325 
  middle tertile (125-136) top tertile (≥ 85) 0.75 (0.37-1.52) 0.425 
top tertile (≥ 137) top tertile (≥ 85) 1.06 (0.66-1.71) 0.808 
 
Adjusted for age, sex, BMI, SBP, DBP, HbA1c, FPG, LDL cholesterol, HDL cholesterol, TG, and smoking status. Abbreviations: BMI, body mass 
index; CI, confidence interval; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HDL, high-density 
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TRDED, treatment-required diabetic eye diseases. 
 
n=280,329 
 Participants aged 19-72 years who had been followed for at least 3 years from 1 April  
2008 to 31 March 2012 were included and followed to 31 August 2015. 
n=17,158 
Study participants 
n = 12,242 
Excluded  
Did not have diabetes mellitus 
 Previous TRDED events 
(n=263,171) 
Excluded 
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Figure S2. Cumulative incidence of TRDED according to six categories of HbA1c 
determined by the Kaplan-Meier method. 
 
Six categories of HbA1c (thick dotted line, HbA1c ≥8.6%; thick black line, 8.1-8.5%; thick 
dashed line, 7.6-8.0%; thin dotted line, 7.1-7.5%; thin black line, 6.6-7.0%; thin dashed line, 
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Figure S3. Combined roles of PP with HbA1c (A) and SBP with HbA1c (B) for TRDED. 
 
 
Each variable was stratified according to tertiles. The estimated log hazard ratios were plotted as 
connected points with confidence intervals. HbA1c (dotted line, HbA1c ≥7.0%; black line, HbA1c 
6.5-6.9%; dashed line, HbA1c ≤6.4%) levels at baseline. HbA1c, hemoglobin A1c; HR, hazard ratio; 
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